Lisa Beth Nachtigall, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acromegaly | 23 | 2024 | 304 | 6.870 |
Why?
|
Pituitary Neoplasms | 14 | 2024 | 1306 | 2.760 |
Why?
|
Hyperprolactinemia | 6 | 2022 | 126 | 1.970 |
Why?
|
Adenoma | 12 | 2024 | 2138 | 1.930 |
Why?
|
Somatostatin | 7 | 2021 | 443 | 1.680 |
Why?
|
Growth Hormone-Secreting Pituitary Adenoma | 4 | 2024 | 49 | 1.380 |
Why?
|
Octreotide | 5 | 2024 | 149 | 1.360 |
Why?
|
Human Growth Hormone | 11 | 2024 | 632 | 1.260 |
Why?
|
Pituitary ACTH Hypersecretion | 4 | 2024 | 177 | 1.100 |
Why?
|
Peptides, Cyclic | 3 | 2016 | 393 | 1.010 |
Why?
|
Adrenal Insufficiency | 3 | 2024 | 190 | 0.990 |
Why?
|
Ergolines | 3 | 2017 | 57 | 0.940 |
Why?
|
Insulin-Like Growth Factor I | 14 | 2022 | 1905 | 0.920 |
Why?
|
Gadolinium | 2 | 2019 | 945 | 0.910 |
Why?
|
Pituitary Apoplexy | 2 | 2021 | 29 | 0.820 |
Why?
|
Hypopituitarism | 6 | 2019 | 247 | 0.820 |
Why?
|
Multiple Endocrine Neoplasia Type 1 | 1 | 2020 | 43 | 0.710 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2024 | 1510 | 0.640 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2020 | 159 | 0.600 |
Why?
|
Dopamine Agonists | 3 | 2017 | 349 | 0.580 |
Why?
|
Pituitary Gland | 6 | 2023 | 634 | 0.570 |
Why?
|
User-Computer Interface | 1 | 2022 | 1404 | 0.500 |
Why?
|
Estrogen Replacement Therapy | 7 | 2009 | 1207 | 0.450 |
Why?
|
Pilot Projects | 5 | 2023 | 8370 | 0.430 |
Why?
|
Gonadotropin-Releasing Hormone | 7 | 2022 | 1158 | 0.410 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2193 | 0.390 |
Why?
|
Patient Education as Topic | 1 | 2022 | 2278 | 0.390 |
Why?
|
Menopause | 2 | 2019 | 1615 | 0.390 |
Why?
|
Magnetic Resonance Imaging | 7 | 2024 | 35784 | 0.390 |
Why?
|
Hydrocortisone | 6 | 2024 | 1776 | 0.350 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8511 | 0.340 |
Why?
|
Antineoplastic Agents | 4 | 2016 | 13538 | 0.330 |
Why?
|
Estrogens | 6 | 2009 | 1520 | 0.330 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 3476 | 0.300 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4485 | 0.300 |
Why?
|
Emotions | 2 | 2019 | 2672 | 0.300 |
Why?
|
Heart Valves | 1 | 2009 | 282 | 0.290 |
Why?
|
Sex Hormone-Binding Globulin | 2 | 2000 | 543 | 0.270 |
Why?
|
Pituitary Irradiation | 1 | 2005 | 14 | 0.270 |
Why?
|
Contrast Media | 1 | 2019 | 5253 | 0.260 |
Why?
|
Retrospective Studies | 20 | 2024 | 78297 | 0.250 |
Why?
|
Adult | 44 | 2024 | 214958 | 0.250 |
Why?
|
Middle Aged | 42 | 2024 | 214412 | 0.230 |
Why?
|
Humans | 70 | 2024 | 746044 | 0.230 |
Why?
|
Female | 50 | 2024 | 382109 | 0.230 |
Why?
|
Administration, Oral | 6 | 2024 | 3966 | 0.230 |
Why?
|
Hypogonadism | 4 | 1997 | 789 | 0.230 |
Why?
|
Growth Hormone | 3 | 2022 | 555 | 0.220 |
Why?
|
Saliva | 2 | 2018 | 786 | 0.210 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 962 | 0.210 |
Why?
|
Pituitary Diseases | 1 | 2023 | 135 | 0.210 |
Why?
|
Male | 41 | 2024 | 351093 | 0.200 |
Why?
|
Inhibins | 3 | 1997 | 213 | 0.200 |
Why?
|
Quality of Life | 10 | 2024 | 12984 | 0.200 |
Why?
|
Loss of Heterozygosity | 1 | 2024 | 665 | 0.200 |
Why?
|
Antidepressive Agents | 1 | 2013 | 2864 | 0.190 |
Why?
|
Calcium | 1 | 2014 | 5654 | 0.190 |
Why?
|
Postmenopause | 4 | 2009 | 2461 | 0.190 |
Why?
|
Vitamin D | 1 | 2014 | 3239 | 0.180 |
Why?
|
Standard of Care | 1 | 2024 | 547 | 0.180 |
Why?
|
Antipsychotic Agents | 1 | 2013 | 3053 | 0.180 |
Why?
|
Aged | 29 | 2024 | 164236 | 0.170 |
Why?
|
Diabetes Insipidus, Neurogenic | 2 | 2013 | 20 | 0.170 |
Why?
|
Estrone | 1 | 2000 | 233 | 0.170 |
Why?
|
Self Report | 3 | 2022 | 3589 | 0.170 |
Why?
|
Prolactin | 2 | 2013 | 627 | 0.170 |
Why?
|
Diabetes Insipidus | 1 | 2019 | 147 | 0.160 |
Why?
|
Sex Characteristics | 1 | 2009 | 2558 | 0.160 |
Why?
|
Headache | 1 | 2006 | 1223 | 0.160 |
Why?
|
Heart | 2 | 2024 | 4361 | 0.150 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 222 | 0.150 |
Why?
|
Neuroendocrine Tumors | 1 | 2024 | 642 | 0.150 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9105 | 0.150 |
Why?
|
Postoperative Period | 2 | 2020 | 1804 | 0.150 |
Why?
|
Testis | 2 | 1997 | 792 | 0.140 |
Why?
|
Cranial Irradiation | 1 | 2019 | 393 | 0.130 |
Why?
|
Melanoma | 1 | 2014 | 5569 | 0.130 |
Why?
|
Oxytocin | 1 | 2019 | 397 | 0.130 |
Why?
|
Aged, 80 and over | 12 | 2020 | 57557 | 0.120 |
Why?
|
Radiation Injuries | 2 | 2019 | 1175 | 0.120 |
Why?
|
Longitudinal Studies | 3 | 2023 | 14113 | 0.120 |
Why?
|
Radius | 1 | 2017 | 439 | 0.120 |
Why?
|
Receptors, Prolactin | 1 | 2013 | 16 | 0.110 |
Why?
|
Infertility, Male | 1 | 1997 | 399 | 0.110 |
Why?
|
Polyuria | 1 | 2013 | 38 | 0.110 |
Why?
|
Progestins | 1 | 1995 | 299 | 0.110 |
Why?
|
Thyrotropin | 2 | 2014 | 830 | 0.110 |
Why?
|
Puberty | 1 | 1996 | 490 | 0.110 |
Why?
|
Estradiol | 1 | 2000 | 1941 | 0.110 |
Why?
|
Petrosal Sinus Sampling | 1 | 2012 | 22 | 0.110 |
Why?
|
Capsules | 2 | 2024 | 193 | 0.100 |
Why?
|
Glioma | 2 | 2019 | 3373 | 0.100 |
Why?
|
Corticotropin-Releasing Hormone | 2 | 2012 | 360 | 0.100 |
Why?
|
Endometrium | 2 | 1995 | 423 | 0.100 |
Why?
|
Impulsive Behavior | 1 | 2014 | 331 | 0.100 |
Why?
|
Treatment Outcome | 12 | 2024 | 63661 | 0.100 |
Why?
|
Case-Control Studies | 4 | 2016 | 21673 | 0.090 |
Why?
|
Arthritis, Rheumatoid | 1 | 2006 | 3734 | 0.090 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 4056 | 0.090 |
Why?
|
Dacarbazine | 1 | 2013 | 559 | 0.090 |
Why?
|
Testosterone | 4 | 2013 | 2440 | 0.090 |
Why?
|
Follicle Stimulating Hormone | 4 | 2022 | 724 | 0.090 |
Why?
|
Uterine Hemorrhage | 2 | 1996 | 246 | 0.090 |
Why?
|
Meningioma | 1 | 2019 | 1203 | 0.090 |
Why?
|
Luteinizing Hormone | 4 | 2022 | 826 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2019 | 1227 | 0.090 |
Why?
|
Follow-Up Studies | 4 | 2020 | 38752 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 615 | 0.080 |
Why?
|
Patient Preference | 1 | 2016 | 891 | 0.080 |
Why?
|
Hormone Antagonists | 1 | 2009 | 106 | 0.080 |
Why?
|
Nose | 1 | 2012 | 510 | 0.080 |
Why?
|
Prolactinoma | 1 | 2009 | 110 | 0.080 |
Why?
|
Cushing Syndrome | 1 | 2009 | 242 | 0.080 |
Why?
|
Mental Health | 1 | 2022 | 3091 | 0.070 |
Why?
|
Drug Delivery Systems | 2 | 1996 | 2208 | 0.070 |
Why?
|
Prognosis | 2 | 2020 | 29068 | 0.070 |
Why?
|
Neurosurgical Procedures | 2 | 2016 | 1988 | 0.070 |
Why?
|
Physicians, Family | 1 | 2008 | 352 | 0.070 |
Why?
|
Young Adult | 7 | 2020 | 57106 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3669 | 0.060 |
Why?
|
Radiosurgery | 1 | 2014 | 1331 | 0.060 |
Why?
|
Bone Density | 1 | 2017 | 3510 | 0.060 |
Why?
|
Hormone Replacement Therapy | 1 | 2010 | 742 | 0.060 |
Why?
|
Growth Disorders | 1 | 2009 | 623 | 0.060 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 25177 | 0.060 |
Why?
|
Hypothalamo-Hypophyseal System | 2 | 2019 | 680 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2019 | 4287 | 0.060 |
Why?
|
Sex Factors | 2 | 2014 | 10279 | 0.060 |
Why?
|
Time Factors | 2 | 2020 | 39587 | 0.060 |
Why?
|
Stereotaxic Techniques | 1 | 2005 | 540 | 0.050 |
Why?
|
Vagina | 2 | 2003 | 805 | 0.050 |
Why?
|
Phenotype | 2 | 2020 | 16245 | 0.050 |
Why?
|
Family Characteristics | 1 | 2008 | 977 | 0.050 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2003 | 130 | 0.050 |
Why?
|
Intra-Abdominal Fat | 1 | 2008 | 580 | 0.050 |
Why?
|
Administration, Cutaneous | 3 | 2009 | 705 | 0.050 |
Why?
|
Body Mass Index | 1 | 2020 | 12633 | 0.050 |
Why?
|
Brain Neoplasms | 3 | 2019 | 8832 | 0.050 |
Why?
|
Dexamethasone | 1 | 2009 | 1919 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2003 | 278 | 0.050 |
Why?
|
Sexuality | 1 | 2003 | 168 | 0.050 |
Why?
|
Cosyntropin | 1 | 2021 | 34 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2022 | 12208 | 0.050 |
Why?
|
Adolescent | 9 | 2019 | 86202 | 0.050 |
Why?
|
Cohort Studies | 1 | 2024 | 40503 | 0.050 |
Why?
|
Placebos | 2 | 2020 | 1658 | 0.050 |
Why?
|
Concanavalin A | 1 | 2000 | 188 | 0.050 |
Why?
|
Depressive Disorder | 1 | 2013 | 3716 | 0.050 |
Why?
|
Receptors, Somatotropin | 1 | 2020 | 58 | 0.050 |
Why?
|
Pregnancy | 2 | 2020 | 29294 | 0.040 |
Why?
|
Radiotherapy Dosage | 2 | 2019 | 2893 | 0.040 |
Why?
|
Prospective Studies | 6 | 2024 | 53218 | 0.040 |
Why?
|
Mutation | 2 | 2024 | 29614 | 0.040 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2000 | 352 | 0.040 |
Why?
|
Arginine Vasopressin | 1 | 2019 | 126 | 0.040 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2012 | 619 | 0.040 |
Why?
|
Periodicity | 2 | 1996 | 348 | 0.040 |
Why?
|
Cardiovascular Diseases | 4 | 2012 | 15308 | 0.040 |
Why?
|
Blood Platelets | 1 | 2009 | 2478 | 0.040 |
Why?
|
Thyroid Function Tests | 1 | 2019 | 289 | 0.040 |
Why?
|
Drug Substitution | 1 | 2020 | 284 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18146 | 0.040 |
Why?
|
Injections | 1 | 2020 | 830 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 6773 | 0.040 |
Why?
|
Gonadotropins, Pituitary | 1 | 1997 | 69 | 0.040 |
Why?
|
Ultrasonography | 1 | 1990 | 5899 | 0.040 |
Why?
|
Body Composition | 3 | 2012 | 2381 | 0.030 |
Why?
|
Libido | 1 | 1997 | 119 | 0.030 |
Why?
|
Echocardiography | 1 | 2009 | 4909 | 0.030 |
Why?
|
Psychopathology | 1 | 2019 | 413 | 0.030 |
Why?
|
Sex Chromosome Aberrations | 1 | 1996 | 115 | 0.030 |
Why?
|
Bipolar Disorder | 1 | 2013 | 5051 | 0.030 |
Why?
|
Kallmann Syndrome | 1 | 1996 | 139 | 0.030 |
Why?
|
Receptors, Retinoic Acid | 1 | 1996 | 225 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 6939 | 0.030 |
Why?
|
Coronary Disease | 1 | 1990 | 5924 | 0.030 |
Why?
|
Disorders of Sex Development | 1 | 1996 | 129 | 0.030 |
Why?
|
Lipoproteins | 2 | 2012 | 881 | 0.030 |
Why?
|
Gonadotropins | 1 | 1996 | 242 | 0.030 |
Why?
|
Circadian Rhythm | 2 | 2018 | 2532 | 0.030 |
Why?
|
Risk Factors | 5 | 2014 | 72416 | 0.030 |
Why?
|
Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.030 |
Why?
|
Child | 4 | 2014 | 78456 | 0.030 |
Why?
|
Erectile Dysfunction | 1 | 1997 | 453 | 0.030 |
Why?
|
Reference Values | 2 | 1997 | 4875 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 1730 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 547 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 1997 | 20750 | 0.020 |
Why?
|
Age of Onset | 1 | 1997 | 3241 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2361 | 0.020 |
Why?
|
Lipids | 2 | 2012 | 3290 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 660 | 0.020 |
Why?
|
Astrocytoma | 1 | 2013 | 775 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14537 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 7935 | 0.020 |
Why?
|
Protein Binding | 1 | 2000 | 9278 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6453 | 0.020 |
Why?
|
Estriol | 1 | 1966 | 52 | 0.020 |
Why?
|
Mood Disorders | 1 | 2013 | 1103 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2841 | 0.020 |
Why?
|
Algorithms | 1 | 2006 | 13796 | 0.020 |
Why?
|
Affect | 1 | 2013 | 1459 | 0.020 |
Why?
|
Repressor Proteins | 1 | 1996 | 2964 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 1990 | 776 | 0.020 |
Why?
|
Drug Interactions | 1 | 2009 | 1412 | 0.020 |
Why?
|
Psychometrics | 1 | 2014 | 2993 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6781 | 0.010 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2004 | 59 | 0.010 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1853 | 0.010 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2003 | 63 | 0.010 |
Why?
|
Administration, Intravaginal | 1 | 2003 | 144 | 0.010 |
Why?
|
Recurrence | 1 | 2015 | 8373 | 0.010 |
Why?
|
Diabetes Complications | 1 | 1990 | 1318 | 0.010 |
Why?
|
Vaginal Diseases | 1 | 2003 | 103 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13303 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4858 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10329 | 0.010 |
Why?
|
Animals | 1 | 2013 | 166331 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9521 | 0.010 |
Why?
|
Atrophy | 1 | 2003 | 1613 | 0.010 |
Why?
|
Biopsy | 1 | 1990 | 6732 | 0.010 |
Why?
|
Blood Glucose | 1 | 2012 | 6213 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2010 | 3751 | 0.010 |
Why?
|
Prevalence | 1 | 2014 | 15308 | 0.010 |
Why?
|
DAX-1 Orphan Nuclear Receptor | 1 | 1996 | 29 | 0.010 |
Why?
|
Transcription Factors | 1 | 1996 | 12039 | 0.010 |
Why?
|
Therapeutic Equivalency | 1 | 1996 | 135 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15009 | 0.010 |
Why?
|
Glucose | 1 | 2008 | 4302 | 0.010 |
Why?
|
Cryptorchidism | 1 | 1996 | 123 | 0.010 |
Why?
|
Olfaction Disorders | 1 | 1996 | 220 | 0.010 |
Why?
|
Adrenal Glands | 1 | 1996 | 556 | 0.010 |
Why?
|
Exercise | 1 | 1990 | 5686 | 0.010 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1996 | 391 | 0.010 |
Why?
|
Smoking | 1 | 1990 | 8975 | 0.010 |
Why?
|
X Chromosome | 1 | 1996 | 811 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 6459 | 0.010 |
Why?
|
Feedback | 1 | 1996 | 780 | 0.010 |
Why?
|
DNA Primers | 1 | 1996 | 2810 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2009 | 19804 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1996 | 2365 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1996 | 4175 | 0.010 |
Why?
|
Hypertension | 1 | 1990 | 8358 | 0.010 |
Why?
|
Mental Disorders | 1 | 2009 | 6637 | 0.010 |
Why?
|
Pedigree | 1 | 1996 | 4555 | 0.000 |
Why?
|
Obesity | 1 | 1990 | 12670 | 0.000 |
Why?
|
Chromatography, Paper | 1 | 1966 | 76 | 0.000 |
Why?
|
Glycosuria | 1 | 1966 | 44 | 0.000 |
Why?
|
Base Sequence | 1 | 1996 | 12447 | 0.000 |
Why?
|
Fetal Death | 1 | 1966 | 433 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 17675 | 0.000 |
Why?
|